Total Payments
$1.4M
2024 Payments
$216,780
Companies
42
Transactions
1,603
Payment Breakdown by Category
Other$1.1M (79.9%)
Travel$193,131 (13.8%)
Food & Beverage$30,339 (2.2%)
Research$29,335 (2.1%)
Consulting$28,222 (2.0%)
Education$184.26 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 417 | 76.8% |
| Travel and Lodging | $193,131 | 581 | 13.8% |
| Long term medical supply or device loan | $43,365 | 9 | 3.1% |
| Food and Beverage | $30,339 | 561 | 2.2% |
| Unspecified | $29,335 | 15 | 2.1% |
| Consulting Fee | $28,222 | 10 | 2.0% |
| Education | $184.26 | 10 | 0.0% |
Payments by Type
General
$1.4M
1,588 transactions
Research
$29,335
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amarin Pharma Inc. | $400,781 | 528 | $0 (2024) |
| Novo Nordisk Inc | $250,541 | 159 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $190,384 | 172 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $174,074 | 225 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $109,962 | 157 | $0 (2019) |
| Lilly USA, LLC | $92,980 | 89 | $0 (2024) |
| Esperion Therapeutics, Inc. | $67,617 | 66 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $51,785 | 30 | $0 (2024) |
| PTC Therapeutics, Inc. | $20,713 | 8 | $0 (2024) |
| UIH America, Inc. | $11,526 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $216,780 | 170 | Novo Nordisk Inc ($88,376) |
| 2023 | $173,508 | 142 | Novo Nordisk Inc ($58,761) |
| 2022 | $194,878 | 146 | Novo Nordisk Inc ($85,516) |
| 2021 | $120,536 | 116 | Boehringer Ingelheim Pharmaceuticals, Inc. ($39,307) |
| 2020 | $89,344 | 112 | Amarin Pharma Inc. ($37,607) |
| 2019 | $211,340 | 245 | Amarin Pharma Inc. ($134,702) |
| 2018 | $237,385 | 399 | Amarin Pharma Inc. ($132,054) |
| 2017 | $155,984 | 273 | Regeneron Healthcare Solutions, Inc. ($67,358) |
All Payment Transactions
1,603 individual payment records from CMS Open Payments — Page 1 of 65
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,720.00 | General |
| Category: cardiovascular | ||||||
| 12/11/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,720.00 | General |
| Category: cardiovascular | ||||||
| 12/11/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,600.00 | General |
| Category: cardiovascular | ||||||
| 11/21/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $723.95 | General |
| Category: cardiovascular | ||||||
| 11/21/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $345.88 | General |
| Category: cardiovascular | ||||||
| 11/21/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: cardiovascular | ||||||
| 11/21/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $112.40 | General |
| Category: cardiovascular | ||||||
| 11/21/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $85.76 | General |
| Category: cardiovascular | ||||||
| 11/21/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | Cash or cash equivalent | $18.72 | General |
| Category: cardiovascular | ||||||
| 11/17/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $38.53 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/15/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $144.19 | General |
| 11/07/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: Diabetes | ||||||
| 11/06/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,720.00 | General |
| Category: cardiovascular | ||||||
| 11/06/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $55.03 | General |
| Category: Cardio-renal | ||||||
| 10/31/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: Cardio-renal | ||||||
| 10/19/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $605.46 | General |
| Category: cardiovascular | ||||||
| 10/19/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $483.26 | General |
| Category: cardiovascular | ||||||
| 10/19/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $462.31 | General |
| Category: cardiovascular | ||||||
| 10/19/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $177.09 | General |
| Category: cardiovascular | ||||||
| 10/19/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $85.76 | General |
| Category: cardiovascular | ||||||
| 10/19/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | Cash or cash equivalent | $67.54 | General |
| Category: cardiovascular | ||||||
| 10/17/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $75.26 | General |
| Category: Endocrinology | ||||||
| 10/17/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $56.15 | General |
| 10/16/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: Diabetes | ||||||
| 10/15/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $10.07 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OF PTC857 IN ADULT SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (CARDINALS) | PTC Therapeutics, Inc. | $10,263 | 5 |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OFPTC857IN ADULT SUBJECTS WITHAMYOTROPHIC LATERAL SCLEROSIS(CARDINALS) | PTC Therapeutics, Inc. | $9,025 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $4,765 | 5 |
| Transform | Cleerly, Inc. | $2,741 | 1 |
| A PHASE 2 STUDY TO ASSESS THE SAFETY, TOLERABILITY, PK, EFFICACY, AND BIOMARKER EFFECTS OF PTC857 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS | PTC Therapeutics, Inc. | $1,425 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,117 | 1 |
About Dr. John Osborne, MD
Dr. John Osborne, MD is a Cardiovascular Disease healthcare provider based in Grapevine, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1114929718.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Osborne, MD has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $216,780 received in 2024. These payments were reported across 1,603 transactions from 42 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.1M).
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Nuclear Cardiology
- Location Grapevine, TX
- Active Since 08/12/2005
- Last Updated 10/30/2012
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1114929718
Products in Payments
- Vascepa (Drug) $400,781
- JARDIANCE (Drug) $280,808
- PRALUENT (Drug) $174,074
- PRALUENT ALIROCUMAB INJECTION (Biological) $108,480
- Ozempic (Drug) $91,080
- NEXLIZET (Drug) $67,313
- KISQALI (Drug) $43,365
- Wegovy (Drug) $18,115
- Rybelsus (Drug) $11,948
- uCT (Device) $11,526
- OCREVUS (Biological) $7,293
- GILENYA (Drug) $5,910
- ENTRESTO (Drug) $2,337
- PRALUENT (Biological) $2,149
- WATCHMAN (Device) $1,373
- Somatom Force (Device) $851.06
- Sotyktu (Drug) $801.35
- LifeVest (Device) $514.41
- CT SCANNER (Device) $414.92
- uCT ATLAS (Device) $348.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Grapevine
Dr. Vikas Jain, M.d, M.D
Cardiovascular Disease — Payments: $374,314
Cardiovascular Disease $374,314
Dr. Paul Bhella, M.d, M.D
Cardiovascular Disease — Payments: $294,139
Cardiovascular Disease $294,139
Raul Santos, Md, MD
Cardiovascular Disease — Payments: $10,376
Cardiovascular Disease $10,376
Dr. John Lawson, Md, MD
Cardiovascular Disease — Payments: $7,403
Cardiovascular Disease $7,403
Dr. Amyn Malik, Md, MD
Cardiovascular Disease — Payments: $4,421
Cardiovascular Disease $4,421
Dr. Richard Feingold, D.o, D.O
Cardiovascular Disease — Payments: $3,790
Cardiovascular Disease $3,790